Lanterna - Chalmers Ventures
chalmers ventures portfolio company


Lanterna’s patent pending FBAs introduce no substantial steric bulk to RNA-sequences and have excellent emissive properties. They enable nucleic acid sequences to form secondary structures with maintained canonical base-pairing and thermodynamic stability. Compared to other labeling options, there is also less impact on lipophilicity. The end result is a labeled nucleic acid that retains more of its native behavior.